Clinical Trials

Clinical Trials for Aptose Biosciences

Aptose Biosciences has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK inhibitor, and APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression.

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Recruiting

This study is being done to evaluate the safety, tolerability and effectiveness of Oral

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas: View Clinical Trial

A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

This study is being done to evaluate the safety, tolerability and antitumor activity of oral

A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia: View Clinical Trial

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Recruiting

This study is being done to evaluate the safety and effectiveness of APTO-253 for the

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS: View Clinical Trial

Enrollment

For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.

Contact Us Visit ClinicalTrials.gov

The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.